Nanobiotix S.A.
NNBXF- Exchange
- OTC
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001760854
No open-market purchases or sales by Nanobiotix S.A. insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Other share classesNBTX
Key figures
- Market capADS ratio not in SEC data
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026
- 0
- 13F valueReported value at the end of Q2 2026
- $0
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in EUR.
- Revenue, FY2025
- EUR 32.6M
- No comparable prior period
- Net income, FY2025
- EUR -24.0M
- No comparable prior period
- Free cash flow, FY2025
- EUR -34.0M
- No comparable prior period
Revenue flow, FY2025
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2025: EUR 24.0M (73.5% of revenue).
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 119.2K
- Shares sold short
- Change
- −685
- −0.6% vs. previous
- Days to cover
- > 999
- Above FINRA's cap of 999.99 days
Superinvestors holding NNBXF, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding NNBXF at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Nanobiotix S.A. insiders from Form 4, newest first.
No open-market purchases or sales by Nanobiotix S.A. insiders are on file.
Top 10 13F holders, Q2 2026
View all: Top 10 13F holders, Q2 2026The largest institutional positions in Nanobiotix S.A. at the end of Q2 2026; share changes are against Q1 2026.
No institution reported holding NNBXF in 13F filings for Q2 2026.